OCT in STEMI Patients: Is It Safe to Prevent Stenting?

Percutaneous coronary intervention in patients with acute myocardial infarction (AMI) where the physiopathological mechanism is plaque erosion or non-atherosclerotic mechanisms (such as spontaneous coronary artery dissection) is not beneficial according to recent studies. 

OCT en pacientes con SCACEST, ¿Es seguro utilizarlo para evitar implante de stent?

The EROSION study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography–Based Management in Plaque Erosion) has shown medical treatment with no stenting might be an option to treat plaque erosion driven AMI. To assess the etiological differences generated by a coronary event using optical coherence tomography (OCT) is ideal.

The aim of this multicenter, prospective, randomized study in STEMI patients followed up at one year, was to examine whether OCT guided revascularization is associated with lower stenting rate vs. conventional angiography guided revascularization. 

Primary effectiveness end point was stent implantation rate in both groups. Safety end point was incidence of the composite of cardiovascular death, repeat MI, target vessel revascularization and unstable angina. Secondary end point included the incidence of cerebro and cardiovascular events at 1 year. 

226 patients were included, 112 in the OCT group and 114 in the angiography group. Mean age was 55, mostly were men. Culprit lesion was most frequently located in the anterior descending (49%) and right coronary arteries (40%).

Read also: RESTORE | Using Rivaroxaban to Prevent Radial Artery Occlusion After an Intervention.

Total stent implantation rate was 51%, OCT presenting the lowest rate compared against the angiography group (43.8% vs 58.8%; P = 0.024). there were no significant differences in secondary end point. 

Conclusion

In STEMI patients with early infarct artery patency with no significative stenosis compared against the angiography guided group, OCT reduced stent implantation rate.  Further study is required to determine the clinical benefits of OCT guided reperfusion.

Dr. Andrés Rodríguez
Member of the Editorial Board in SOLACI.org .

Original Title: EROSION III A Multicenter RCT of OCT-Guided Reperfusion in STEMI With Early Infarct Artery Patency.

Reference: Haibo Jia, MD, PHD et al. J Am Coll Cardiol Intv 2022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | FLAVOUR II: Angiography-Derived FFR-Guided vs. IVUS-Guided PCI

Physiological assessment is effective when it comes to decision-making for percutaneous coronary intervention (PCI). However, despite the available evidence, its use remains limited. AngioFFR...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...